drugset / Trial / NCT04676035

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

NCT04676035

Phase 1 Completed 18 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelBasic science

Summary

The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Timeline

Start
2020-06-15
Primary completion
2022-01-26
Completion
2022-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule
Subject Omeprazole Other / unclassified
Subject Rezvilutamide Small molecule 240 mg
Subject Warfarin Small molecule
Background Vitamin K Unknown

Indications